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Abstract
OBJECTIVES: To investigate the in-hospital health outcome and 10-year survival in patients undergoing redo coronary surgery with (redo-
CABG) or without (redo-OPCAB) cardiopulmonary bypass.
METHODS: A total of 349 redo coronary surgery patients were identified from our registry. Of these, 143 redo-OPCAB patients (40.97%)
were compared with 206 redo-CABG patients. To minimize the bias, we also conducted propensity score matching. In Matched Analysis
A, 111 redo-OPCAB patients with any type of primary cardiac operation were compared with 111 redo-CABG cases. In Matched Analysis
B, 84 redo-OPCAB patients with isolated coronary surgery as their primary operation were compared with 84 redo-CABG patients. We as-
sessed for all 3 analyses a composite of in-hospital mortality, acute kidney injury, stroke and severe low cardiac output requiring intra-
aortic balloon pump. In addition, we assessed 1-, 5-, and 10-year survival.
RESULTS: In the unmatched analysis, redo-CABG was associated with higher usage of intra-aortic balloon pump (10 vs 3%, P = 0.01) and
composite compared with redo-OPCAB (25 vs 16%, P = 0.06) and similar 10-year survival (67.2 vs 68.5%, log-rank test: P = 0.78). Matched
Analysis A showed similar rates of composite (15 vs 21%, P = 0.25) and 10-year survival (65.1 vs 60.8%, log-rank test: P = 0.5). Matched
Analysis B showed reduction of the composite (19 vs 8%, P = 0.04), less in-hospital mortality (5 vs 0%, P = 0.13), 4.5 times less need for intra-
aortic balloon pump (2 vs 11%, P = 0.02) favouring redo-OPCAB and a similar 10-year survival (71.6 vs 71.7%, log-rank test: P = 0.61).
CONCLUSIONS: Redo-OPCAB surgery is feasible, safe and effective with improved in-hospital outcome and similar 10-year survival com-
pared to redo-CABG.
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BACKGROUND
Redo cardiac surgery represents 5–8% of the current surgical
practice [1–4]. In particular, reoperative coronary artery bypass
grafting (redo-CABG) remains challenging [1–4] with prolonged
operation time, bleeding, poor access to coronary targets and
risk of coronary microembolization leading to complications
[2, 3]. Redo-CABG has declined over the last decade to 2.5–4% of
all coronary procedures, probably due to improved platelet in-
hibition [2, 3], use of more arterial conduits or to the use of per-
cutaneous coronary intervention stenting to treat occluded grafts
or new stenosis [5]. Poor risk profile in these patients may trigger
complications associated with prolonged cardiopulmonary by-
pass and cardioplegic arrest time [6]. Studies from North
America, Japan and India have highlighted the use of off-pump
CABG as an alternative to redo coronary surgery (redo-OPCAB)
[1, 6, 7]. However, most of these studies are based on small pa-
tient cohorts, and none of these studies has evaluated the impact
of redo-OPCAB on long-term survival. In this study, we assess the
safety and efficacy of redo-OPCAB versus redo-CABG using a
combined end-point of serious postoperative complications as
well as 1-, 5-, and 10-year survival.
MATERIALS AND METHODS
We undertook a retrospective analysis from our database
registry. Data were prospectively collected, validated and stored
by an independent team as part of the UK National Registry.
The study protocol was in compliance with the local
Institutional Clinical Audit Review Board, and patient consent
was waived.
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Patient selection
Between May 1996 and January 2014, 15 436 patients underwent
isolated coronary surgery. From these, we selected the study
population as shown in Fig. 1. First, 349 patients were identified
to have undergone any redo coronary surgery, with any primary
cardiac procedure (isolated CABG, valve only or CABG plus
valve/other). Of these, 143 (40.97%) received redo-OPCAB and
represented the study group. The remaining 206 patients
(59.03%) received redo-CABG and formed the control group.
Next, we selected a subgroup of 273 of 349 redo patients with
isolated coronary surgery only being the primary procedure. Of
these, 100 patients (36.6%) underwent redo-OPCAB and 173 pa-
tients (63.4%) underwent redo-CABG.
Data collection and clinical management
Baseline data included clinical characteristics, symptom status,
past medical history, markers of renal function including serum
creatinine (SCrea) and estimated glomerular filtration rate.
Postoperative levels of SCrea were obtained from medical re-
cords and estimated glomerular filtration rate calculated accord-
ingly [8]. Indication for surgery was based on coronary
angiography. The use of redo-OPCAB was based on surgeons
using predominantly OPCAB or CABG with none undertaking a
mixed practice. The OPCAB technique used was as previously re-
ported [9, 10] using pressure stabilizer and intracoronary shunts.
Anaesthesia and perfusion techniques were also as previously re-
ported [11–14].
Computed tomography angiography was used according to
surgeon preference to ascertain the anatomical relation of the
heart and grafts with the re-entry route. Left ventricular ejection
fraction was derived from baseline echocardiogram or left ventri-
culogram. Our definition of reduced left ventricular ejection frac-
tion was <50%. Intraoperative and postoperative data collection
and clinical management were as previously reported [8].
Patients developing non-cardiac single organ renal, respiratory
and/or neurological dysfunction/failure were treated till com-
plete recovery and referred to a specialist centre for further man-
agement beyond the 30-days cut-off, if necessary.
Outcome measures and definitions
The selected composite end-point included: in-hospital mortality,
acute kidney injury (AKI), cerebrovascular accidents and severe
low cardiac output (LCO), requiring intraoperative or postopera-
tive intra-aortic balloon pump (IABP). Reopening for bleeding
and length of hospital stay were also recorded. We also assessed
1-, 5- and 10-year survival. In-hospital mortality was defined as
death by any cause occurred at any time before discharge from
index hospitalization, regardless the length of hospital stay. The
30-day mortality was defined as death within 30 days from sur-
gery even if occurring after discharge. Cerebrovascular was
defined as any new postoperative stroke confirmed by computed
tomography scan. AKI was defined according to the Risk, Injury,
Failure, Loss, and End stage (RIFLE) criteria [14]. The highest post-
operative creatinine value recorded was used to compare with
baseline value, bearing in mind that RIFLE criteria require SCrea
to increase by at least 50% from baseline value to be classified as
AKI [14]. Severe LCO was defined as any intraoperative or post-
operative LCO requiring the use of IABP. Late survival data were
obtained from the UK National Health Service (NHS) tracing ser-
vice to identify non-survivors and date of late any-cause death,
with the latest data obtained in February 2015.
Statistical analysis
Data are presented as mean ± one SD for continuous variables or
as percentages for dichotomous variables. Continuous numerical
variables were tested for normality using the Shapiro–Wilk test
and then compared between groups with unpaired Student’s
t-test if normally distributed or Mann–Whitney U-test if not nor-
mally distributed. In the case of dichotomous variables, Pearson’s
v2 or Fisher’s exact test were used as appropriate. Predictors for
composite outcome were tested using a multivariable logistic re-
gression model: a stepwise selective approach was conducted by
backward and forward selection methods using Akaike informa-
tion criterion as discrimination criterion between models. Event-
free survival curves were compared between the groups by
Kaplan–Meier method and subsequently compared with the log-
rank test. To further adjust for patient selection and preoperative
Figure 1: Diagram of patient’s selection.
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characteristics, we developed 2 propensity score-matched ana-
lyses including in the analysis all the baseline variables available.
In Matched Analysis A, we included all the identified redo coron-
ary surgery patients, regardless of the type of primary operation.
In Matched Analysis B, we included only patients who had
undergone isolated coronary surgery as their primary operation.
In both cases, patients undergoing redo-OPCAB were matched
(1:1) to the group undergoing redo-CABG by all the preoperative
variables. Intraoperative variables were not included in the model
as they occurred during the surgery. The nearest neighbour
method was used with a caliper of 0.2 and the balance after
matching was evaluated with standardized mean differences.
After propensity score matching, variables were compared using
paired Student’s t-test or paired Wilcoxon test for continuous
variables and McNemar (for dichotomous variables) and v2 test
for ordinal categorical variables. A conditional logistic regression
model was developed to evaluate the predictors of the compos-
ite outcome including the same variables used for the non-
matched unconditional logistic regression plus the matching
index. All tests were two-sided with the a level set at 0.05 for stat-
istical significance. Clinical data were recorded and subsequently
tabulated with Microsoft Excel (VR Microsoft Corp, Redmond, WA,
USA). The statistical analysis was computed using R version 3.0.2
[R Core Team (2014), R Foundation for Statistical Computing,
Vienna, Austria]. The propensity score matching was computed
with the package MatchIt [15].
RESULTS
Unmatched analysis
Baseline patient characteristics are presented in Table 1. The
overall mean age was 66.6 ± 8.5 years and 53 patients (15%) were
female. Patients in the redo-OPCAB group were on average
2 years older (67.8 ± 8.1 vs 65.7 ± 8.6 years, P = 0.02) and had twice
the amount of peripheral vascular disease (27% vs 16%, P = 0.02).
The average number of diseased coronary vessels was lower in
the redo-OPCAB (2.3 ± 0.8 vs 2.6 ± 0.6, P < 0.01) reflecting the
number of bypass grafts performed (2.3 ± 0.8 vs 2.6 ± 0.6,
P < 0.01). Completeness of revascularization was similar at 76% vs
73% redo-OPCAB vs redo-CABG respectively (P = 0.9).
Postoperative outcomes are shown in Table 2. The incidence of
the composite end-point was higher in the redo-CABG group
(25% vs 16%, P = 0.06). In-hospital mortality was 2.8 times higher
in the redo-CABG group (6 vs 2%, P = 0.09). The other variables
of the composite included: postoperative AKI (16 vs 13%,
P = 0.43), stroke (1 vs 1%, P = 0.78) and severe LCO needing IABP
(10 vs 3%, P =0.01), all redo-CABG vs redo-OPCAB respectively.
Peak of postoperative SCrea was 134.7 ± 85.1 mmol/l and
126.04 ± 62.3 mmol/l for the redo-CABG and redo-OPCAB re-
spectively (P = 0.30). Reopening for bleeding was higher in redo-
CABG group (3 vs 1%, P =0.19), while hospital stay was 0.6 days
longer (8.8 ± 6.9 vs 8.2 ± 6.2 days, P = 0.07) in the same group.
Table 1: Pre- and intraoperative characteristics
Unmatched analysis
Overall (n = 349) Redo-OPCAB (n = 143) Redo-CABG (n = 206) P-value
Age (years) 66.6 (8.5) 67.8 (8.1) 65.7 (8.6) 0.02
Female gender (%) 53 (15) 21 (15) 32 (15.5) 0.82
BMI (kg/m2) 27.2 (4.2) 27.9 (4.4) 26.9 (4.7) 0.07
Reduced LVEF <50% 117 (33) 46 (32) 71 (34) 0.65
Diabetes (%) 78 (22) 31 (22) 47 (23) 0.80
Hypertension (%) 252 (72) 110 (77) 142 (69) 0.08
CKD (%) 6 (2) 2 (1) 4 (2) 0.70
Preoperative creatinine (mmol/l) 103.1 (29) 101.8 (26.3) 103.9 (30.8) 0.52
eGFR (ml/min/1.73 m2) 64.4 (16.8) 64.7 (16.4) 64.2 (17.1) 0.76
Previous CVA (%) 40 (11) 18 (13) 22 (11) 0.56
PVD (%) 72 (21) 38 (27) 34 (16) 0.02
COPD (%) 53 (15) 25 (17) 28 (14) 0.31
Smoking history (%) 266 (76) 110 (77) 156 (76) 0.76
EuroSCORE 7 (2.7) 6.9 (2.5) 7.2 (2.8) 0.49
NYHA Class 3 or 4 (%) 149 (43) 53 (37) 96 (47) 0.10
CCS Class 3 or 4 (%) 228 (65) 89 (62) 139 (67) 0.37
Urgent surgery (%) 138 (39) 57 (40) 81 (39) 0.91
Previous surgical procedure (%) 0.03
CABG 273 (78) 100 (71) 173 (83)
Valve 43 (12) 23 (16) 20 (10)
CABG + valve ± other 33 (9) 18 (13) 15 (7)
Number of diseased vessels 2.4 (0.7) 2.3 (0.8) 2.6 (0.6) <0.01
Use of nitrates (%) 53 (15) 19 (13) 34 (16) 0.41
Number of grafts 2.5 (0.7) 2.3 (0.8) 2.6 (0.6) <0.01
Use of IMA (%) 175 (50) 81 (57) 94 (46) 0.06
Use of radial artery (%) 67 (19) 32 (22) 35 (17) 0.26
Data are reported as mean and SD for continuous variables and as total count and percentages for categorical variables.
BMI: body mass index; LVEF: left ventricular ejection fraction; CKD: chronic kidney disease; eGFR: estimated glomerular filtration rate; CVA: cerebrovascular
accident; PVD: peripheral vascular disease; COPD: chronic obstructive pulmonary disease; NYHA: New York Heart Association; CCS: Canadian Cardiovasular
Society; CABG: coronary artery bypass grafting; CAD: coronary artery disease; IMA: internal mammary artery.
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The mean follow-up time was 8.88 ± 5.1 years for the entire
population. Figure 2 shows the Kaplan–Meier survival curves for
the 2 unmatched groups. The long-term survival was similar be-
tween groups (log-rank test: P = 0.78). Late survival at 1-, 5- and
10-year was similar between groups at 95 vs 91.3%, 86.7 vs
83.5%, and 67.2 vs 68.4% for redo-OPCAB vs redo-CABG re-
spectively. A multivariate logistic regression model indicated
body mass index [odds ratio (OR_ 0.93, 95% confidence interval
(CI) 0.86–0.99, P = 0.04) and EuroSCORE (OR 1.18, 95% CI 1.06–
1.31, P = 0.01) as independent predictors of the composite
outcome.
Propensity score matching analyses A and B
Distribution of baseline characteristics for both matched analyses
A and B was similar between groups (Table 3).
Matched Analysis A. In propensity score-Matched Analysis
A the number of patients was 111 in each group, including
those who had undergone any type of primary surgery (CABG
only, valve only and CABG plus valve with/without other).
Postoperative outcomes are shown in Table 4. The rate of the
composite end-point was 21% in the redo-CABG and 17% in
the redo-OPCAB groups (P = 0.25). This included in-hospital
mortality (4 vs 2%, P = 0.25), AKI (14% vs 12%, P = 0.56), stroke
(1% vs 1%, P = 1) and severe LCO requiring IABP (10 vs 3%,
P = 0.03), all redo-CABG vs redo-OPCAB. Reopening for bleed-
ing was 4 times higher in the redo-CABG group (4% vs 1%,
P = 0.17) and the length of stay was slightly longer in the redo-
CABG group (8.7 ± 5.6 vs 8.1 ± 5.6 days, P = 0.18). Peak of post-
operative SCrea was 127.9 ± 59.8 mmol/l and 123.3 ± 60.5 mmol/
l for redo-CABG and redo-OPCAB, respectively (P = 0.34).
Figure 3A shows the Kaplan–Meier survival curves. The long-
term survival was similar between groups (log-rank test:
P = 0.5). Late survival at 1, 5 and 10 years was similar between
groups at 94.6 vs 91%, 83.2 vs 79.8% and 65.1 vs 60.8% for
redo-OPCAB vs redo-CABG, respectively. The number of graft
was higher in the redo-CABG group (2.4 ± 0.8 vs 2.1 ± 0.8,
P <0.01). After stepwise selection process, the multivariable lo-
gistic regression model included EuroSCORE (OR = 1.25, 95%
CI: 0.99–1.59, P = 0.06) and preoperative creatinine (OR = 1.02,
95% CI 0.99–1.04, P = 0.15) as predictors of composite
outcome.
Matched Analysis B. In propensity score-Matched Analysis
B, the number of patients was 84 in each group, including those
undergone isolated CABG only as the primary operation.
Postoperative outcomes are shown in Table 4. The rate of the
composite end-point was reduced in the redo-OPCAB group
(19 vs 8%, P = 0.04) and distributed as follows: in-hospital mor-
tality (5 vs 0%, P = 0.13), AKI (11 vs 6%, P = 0.24), stroke (0% vs
0.0%, P = NA) and severe LCO requiring IABP (11 vs 2%,
P = 0.02), all redo-CABG vs redo-OPCAB, respectively.
Reopening for bleeding was 1% vs 0.0% (P = 1), completeness of
revascularization was 71 vs 68% (P = 0.6) and length of stay was
8.5 ± 5.4 vs 8.5 ± 5 days (P = 0.17), all redo-CABG vs redo-
OPCAB, respectively. Peak of postoperative SCrea was
135.3 ± 100.6 mmol/l and 110 ± 45 mmol/l for redo-CABG and
redo-OPCAB, respectively (P = 0.01). Figure 3B shows the
Kaplan–Meier survival for the 2 groups. The long-term survival
was similar between groups (log-rank test: P = 0.61). Late sur-
vival at 1, 5, and 10 years was 97.6 vs 95.2%, 87.5 vs 88.9% and
71.6 vs 71.7% for redo-OPCAB vs redo-CABG, respectively. The
multivariable logistic regression model identified redo-CABG
(OR = 3.83, 95% CI: 1.14–12.8, P = 0.03) and urgent surgery
Table 2: Operative outcomes in the unmatched population
Unmatched analysis
Overall (n = 349) Redo-OPCAB (n = 143) Redo-CABG (n = 206) P-value
In-hospital mortality (%) 15 (4) 3 (2) 12 (6) 0.09
AKI (%) 50 (14) 18 (13) 32 (16) 0.43
CVA (%) 3 (1) 1 (1) 2 (1) 0.78
Use of IABP (%) 25 (7) 4 (3) 21 (10) 0.01
Composite outcome (%) 73 (21) 23 (16) 50 (25) 0.06
Reoperation for bleeding (%) 8 (2) 1 (1) 7 (3) 0.19
Completeness of revascularization (%) 257 (74) 108 (76) 149 (73) 0.92
Hospital stay (days) 8.6 (6.6) 8.2 (6.2) 8.8 (6.9) 0.07
Data are reported as mean and SD for continuous variables and as total count and percentages for categorical variables.
AKI: acute kidney injury (defined as peak of postoperative creatinine >% higher than preoperative value); CVA: cerebrovascular accident; IABP: intra-aortic bal-
loon pump (either intraoperative or postoperative).
Figure 2: Kaplan–Meier survival curves for redo-OPCAB and redo-CABG for
the entire cohort.
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(OR = 9.8, 95% CI 0.91–104.2, P = 0.06) as predictors for compos-
ite outcome.
DISCUSSION
Only few studies have reported on the use of OPCAB technique
for redo coronary surgery [1, 6, 16–19]. The largest report in 617
patients from Japan focuses on in-hospital outcome only with no
late survival and suggests that redo-OPCAB surgery is associated
with lower 30 days mortality (3.5 vs 7%) and less complications
(11 vs 21.5%) compared to redo-CABG [1]. Other studies from
North America and India have reported on redo-OPCAB, al-
though in small cohorts [1, 7, 17, 18, 20, 21].
Our unmatched analysis suggests that redo-OPCAB is associ-
ated with reduced composite end-point and similar 10-year sur-
vival when compared with redo-CABG. In this analysis, the effect
size of redo-OPCAB appears marked for mortality and need for
Table 3: Pre- and intraoperative characteristics of patients in matched analysis
Characteristic Matched Analysis A Matched Analysis B
Redo-OPCAB
(n = 111)
Redo-CABG
(n = 111)
P-value SMD* Redo-OPCAB
(n = 88)
Redo-CABG
(n = 88)
P-value SMD*
Age (years) 67.8 (8.6) 67.9 (7.2) 0.53 0.01 67.3 (7.7) 67.7 (7.5) 0.74 0.05
Female gender (%) 15 (13) 12 (11) 0.54 0.08 11 (13) 9 (11) 0.65 0.07
BMI (kg/m2) 27.4 (3.7) 27.1 (4) 0.49 0.09 27.8 (3.9) 27.4 (4.3) 0.65 0.08
Reduced LVEF <50% 40 (36) 38 (34) 0.78 0.04 29 (34) 30 (36) 0.86 0.03
Diabetes (%) 26 (23) 29 (26) 0.63 0.06 19 (23) 23 (27) 0.44 0.11
Hypertension (%) 83 (75) 81 (73) 0.76 0.04 60 (71) 62 (74) 0.70 0.05
CKD (%) 1 (1) 1 (1) 1.00 <0.01 0 (0) 1 (1) NA 0.16
Preop creatinine (mmol/l) 100.1 (25.4) 102 (29) 0.76 0.07 96.7 (20) 98.6 (24) 0.82 0.08
eGFR (ml/min/1.73 m2) 66 (16) 65.8 (18) 0.84 0.01 67.9 (16) 67.7 (17.7) 0.83 0.01
Previous CVA (%) 15 (13) 14 (13) 0.84 0.03 9 (11) 9 (11) 1.00 <0.01
PVD (%) 23 (21) 25 (22) 0.73 0.04 13 (15) 15 (18) 0.66 0.06
COPD (%) 20 (18) 17 (15) 0.59 0.07 10 (12) 8 (9) 0.59 0.08
Smoking history (%) 82 (73) 81 (73) 0.88 0.02 65 (78) 60 (71) 0.35 0.14
EuroSCORE 7 (2.7) 6.9 (2.7) 0.83 0.05 7.1 (2.5) 7.2 (2.8) 0.71 0.06
NYHA Class 3/4 (%) 43 (39) 44 (40) 0.89 0.02 35 (42) 33 (39) 0.76 0.05
CCS Class 3/4 (%) 67 (60) 73 (66) 0.43 0.11 57 (68) 55 (65) 0.73 0.05
Urgent surgery (%) 44 (40) 48 (44) 0.57 0.07 33 (39) 28 (33) 0.41 0.12
Previous type of surgery (%) 0.91 0.06
CABG 84 (76) 83 (75) NA NA
Valve 16 (14) 18 (16) NA NA
CABG + valve ± other 11 (10) 10 (9) NA NA
Number of diseased vessels 2.4 (0.7) 2.4 (0.7) 0.79 0.03 2.3 (0.8) 2.4 (0.7) 0.29 0.13
Use of nitrates (%) 18 (16) 17 (15) 0.84 0.03 11 (13) 10 (12) 0.78 0.04
No of grafts 2.1 (0.8) 2.4 (0.8) <0.01 2 (0.8) 2.2 (0.8) 0.03
Use of IMA (%) 62 (56) 52 (47) 0.21 44 (51) 29 (34) 0.02
Use of radial artery (%) 24 (22) 19 (17) 0.39 20 (24) 16 (19) 0.47
Data are reported as mean and SD for continuous variables and as total count and percentages for categorical variable.
SMD: standardized mean difference (reported for the variables included in the propensity score matching process); BMI: body mass index; LVEF: Left ventricu-
lar ejection fraction; CKD: chronic kidney disease; CVA: cerebrovascular accident; PVD: peripheral vascular disease; COPD: chronic obstructive pulmonary dis-
ease; NYHA: New York Heart Association; CCS: Canadian Cardiovascular Society.
aSMD (reported for the variables included in the propensity score-matching process).
Table 4: Operative outcomes in matched analysis
Matched Analysis A Matched Analysis B
Characteristic Redo-OPCAB (n = 111) Redo-CABG (n = 111) P-value Redo-OPCAB (n = 84) Redo-CABG (n = 84) P-value
In-hospital mortality (%) 2 (2) 5 (4) 0.25 0 (0.0) 4 (5) 0.13
AKI (%) 13 (12) 16 (14) 0.56 5 (6) 9 (11) 0.24
CVA (%) 1 (1) 1 (1) 1.00 0 (0) 0 (0) NA
Usage of IABP (%) 3 (3) 10 (10) 0.03 2 (2) 9 (11) 0.02
Composite outcome (%) 17 (15) 23 (21) 0.25 7 (8) 16 (19) 0.04
Reoperation for bleeding (%) 1 (1) 4 (4) 0.17 0 (0) 1 (1) 1.00
Completeness of revascularization (%) 77 (69) 91 (82) 0.02 57 (68) 60 (71) 0.60
Hospital stay 8.1 (6.2) 8.67 (5.6) 0.15 8 (5.4) 8.5 (5) 0.17
AKI: acute kidney injury (defined as peak of postoperative creatinine >% higher than preoperative value); CVA: cerebrovascular accident; IABP: intra-aortic bal-
loon pump (either intraoperatively or postoperatively only).
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IABP that were 3 times more common in the redo-CABG group.
Our propensity score-Matched Analysis A (any cardiac procedure
as primary operation) showed no differences in early composite
end-point (21 vs 15%) and 10-year survival (65.1 vs 60.8%) be-
tween redo-CABG and redo-OPCAB, respectively. Conversely, the
propensity score-Matched Analysis B (isolated coronary surgery
as primary operation) showed a reduction in the early composite
end-point by >50% (19 vs 8%), with marked difference in mortal-
ity (5 times lower—5 vs 0%, P = 0.13) and severe LCO needing
IABP (4.5 times lower—11 vs 2%, P = 0.02), both favouring redo-
OPCAB; 10-year survival was similar to redo-CABG (71.6% vs
71.7%), respectively.
The 30-day mortality for redo-OPCAB in Matched Analysis B
was lower than that reported in the Japanese study (1.1% vs
3.5%). This difference could reflect differences in risk profile.
However, in both studies redo-OPCAB was associated with lower
mortality than redo-CABG. This is confirmed by others. Sabik et
al. reported the outcome of 4518 redo-CABG reoperations [2]
with mortality at 4.3% for first redo, 5.1% for second redo and
6.4% for third redo or more. Similar results were reported by
Ghanta et al. in 72 322 redo-CABG procedures from the STS
database [3].
Our study and the report by Dohi et al. [1] also suggest less
postoperative complications following redo-OPCAB. Others have
reported more complications following redo-OPCAB than our
study, although still less than the rate observed for the redo-
CABG groups. Morris et al. [22] reported 41.3% of postoperative
complications after redo-CABG vs 25% after redo-OPCAB
(P <0.01), in keeping with the outcome of a small UK study [23].
Shin and colleagues [18] reported postoperative complication
rates of 64.2% vs 33.3% (P = 0.08) between redo-CABG and redo-
OPCAB, respectively. These findings could explain a tendency for
the shorter hospital stay observed with redo-OPCAB in our study,
which was 0.6, 0.75 and 1.3 days shorter for the unmatched,
Matched B and Matched A analyses, respectively. This is in keep-
ing with the reports by others [1, 18, 20, 22].
The two propensity score-matched analyses of this study sug-
gested that redo-OPCAB may be more effective when used for
redo patients who have undergone isolated coronary surgery as
their primary operation. This is highlighted by the rates of early
composite end-point, which was 8% vs 15% for the redo-OPCAB
groups for Matched Analysis B vs Matched Analysis A, respect-
ively (Table 4). This finding was not observed for redo-CABG co-
horts when using a similar comparative approach.
An important finding of the current study is that in terms of
the 10-year survival redo-OPCAB is as effective as conventional
redo-CABG across all the 3 analyses undertaken. This finding is
reassuring when considering the technical complexity involved in
undertaking coronary anastomoses on the beating heart within
the context of a redo cardiac procedure. This finding is in keep-
ing with the long-term outcome of our previous BHACAS trial re-
porting on long-term graft patency and survival following
primary OPCAB surgery [14].
Our propensity score-Matched Analysis B showed similar
1- and 5-year survival between groups at 97.6 vs 95.2% and 87.5
vs 88.9% for redo-OPCAB vs redo-CABG, respectively. This find-
ing is similar or better than that reported by others following
redo coronary surgery. Usta et al. [19] reported in a small study a
3-year survival rate of 81 ± 12vs 63 ± 9% in redo-OPCAB vs redo-
CABG. Tugtekin et al. [21] reported in another small study a
3-year survival rate of 83.8 vs 88.6% for redo-CABG vs redo-
OPCAB. In a further small study with 43 patients in each group,
actuarial survival at 5-year was 87 ± 5.5% for redo-CABG and
95 ± 3.2% for redo-OPCAB (P = 0.17) [23].
Completeness of coronary revascularization has been associ-
ated with long-term outcome [17, 21, 24]. Some evidence sug-
gests that this may be a limit for OPCAB surgery [25], with a
retrospective analyse suggesting that OPCAB is an independent
predictor of incomplete revascularization [17, 20, 21, 24]. Our
study showed similar completeness of revascularization between
groups in the unmatched analysis but better results in the redo-
CABG group in Matched Analysis A. In Matched Analysis B, com-
pleteness of revascularization favoured only slightly redo-CABG
surgery (71 vs 68%; P = 0.60), although the number of grafts
needed was reduced in the redo-OPCAB group (21 ± 0.8 vs
2.4 ± 0.8; P = 0.03) reflecting the baseline difference in number of
diseased vessels. This finding might reflect a tendency to perform
redo-OPCAB in patients with reduced number of diseased coro-
naries as suggested by others [22], but this speculation cannot be
confirmed in our study.
The ESC/EACTS guidelines suggest that in view of the higher
risk of procedural mortality with redo-CABG and the similar
long-term outcome, percutaneous coronary intervention is the
preferred revascularization strategy in CABG patients requiring
redo revascularization [26]. The findings of our Matched Analysis
B suggests an overall in-hospital mortality of 2.5% (0% for redo-
OPCAB) and 1-, 5-, and 10-year survival rates of 96, 88 and
71.6%, respectively. These remarkable results question the ration-
ale of treating these patients with percutaneous coronary inter-
vention stenting [5] and call for a more in-depth evaluation of
the available evidence.
Figure 3: Kaplan–Meier survival curves for redo-OPCAB and redo-CABG in the
propensity score-Matched Analysis A and Matched Analysis B.
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Limitations
There are several limitations to this study. It is a retrospective sin-
gle-centre analysis in a limited cohort. The allocation of patients
to the study group was by surgeon’s expertise, and this might
have led to undetected difference in risk profile between groups.
The study is from an Institution with historical high interest and
expertise in OPCAB surgery, and this might limit the applicability
of the findings to Institutions with less interest and proficiency in
OPCAB surgery. The study included a patient cohort treated over
a long time period, hence with possible confounding factors due
to changes in clinical practice overtime. Finally, the evaluation of
long-term impact of redo-OPCAB surgery was limited to all-
cause mortality as no data were available on cardiac-related
mortality or late graft patency.
CONCLUSION
In conclusion, this study suggests that redo coronary surgery in
general can be undertaken at low early mortality and at high 1-,
5-, and 10-year survival. It also shows that redo-OPCAB surgery
is feasible and safe in this complex surgical scenario with better
early in-hospital outcome compared to conventional redo-CABG
and comparable high 10-year survival.
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